Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2023 06:30 ET | Source: Transparency Market Research

Venous Procedure Devices Market Poised for US$ 3.4 Billion Growth with a CAGR of 6% by 2030: As per TMR Study

Wilmington, Delaware, United States, June 02, 2023 (GLOBE NEWSWIRE) -- The market for venous procedure devices is expected to reach US$ 3.4 billion by 2030. From 2020 to 2030, the Venous Procedure...
July 12, 2022 09:16 ET | Source: Next Move Strategy Consulting

Global Peripheral Artery Disease (PAD) Devices Market to Reach USD 7.80 Billion by 2030, States a Report by Next Move Strategy Consulting

New York, July 12, 2022 (GLOBE NEWSWIRE) -- According to the report published by Next Move Strategy Consulting, the global peripheral artery disease (PAD) devices market accrued USD 4.02 billion in...
December 27, 2021 08:15 ET | Source: Society for Vascular Surgery

Early Evaluation of Transcarotid Artery Revascularization (TCAR) Versus Carotid Endarterectomy (CEA) Cost-Effectiveness

Rosemont, Ill., Dec. 27, 2021 (GLOBE NEWSWIRE) -- A cost-effectiveness model based on peer-reviewed sources suggests that although five-year costs for transcarotid artery revascularization (TCAR)...
October 19, 2021 09:18 ET | Source: Ambulero

Ambulero’s Gene Therapy Candidate AMB-301 Granted US Orphan Drug Designation For Treatment of Severe Vascular Disease

MIAMI, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Ambulero Inc., a biotechnology company (“Ambulero” or the “Company”) developing new cell and gene therapy treatments for patients suffering from severe...
January 05, 2021 09:15 ET | Source: Society for Vascular Surgery

Study of patients undergoing abdominal aortic aneurysm repair suggests screening guidelines may be inadequate

Rosemont, Ill., Jan. 05, 2021 (GLOBE NEWSWIRE) -- A retrospective study analyzing approximately 55,000 patients undergoing abdominal aortic aneurysm (AAA) repair suggests current AAA screening...
January 28, 2004 08:30 ET | Source: Endovasc Inc.

Two Clinical Sites in Mexico City Join Endovasc's Liprostin Phase II Trial

MONTGOMERY, Texas, Jan. 28, 2004 (PRIMEZONE) -- Endovasc Inc. (OTCBB:EVSC), a drug development company that pioneers new cardiovascular and metabolic drug therapies, announced today that...